Myriad Genetics (MYGN)
4.63
-0.06 (1.28%)
Upcoming Events
Latest Headlines
Form 8-K MYRIAD GENETICS INC For: Jun 04
June 4, 2026 4:09 PM - SEC Filing
Form S-8 MYRIAD GENETICS INC
June 4, 2026 4:08 PM - SEC Filing
Form S-8 MYRIAD GENETICS INC
June 4, 2026 4:06 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Jun 01 Filed by: Jampa Raj
June 2, 2026 4:21 PM - SEC Filing
Form 3 MYRIAD GENETICS INC For: Jun 01 Filed by: Jampa Raj
June 2, 2026 4:15 PM - SEC Filing
Myriad Genetics names Raj Jampa as chief technology officer
June 2, 2026 9:05 AM - StreetInsider
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
June 2, 2026 9:05 AM - StreetInsider
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
May 27, 2026 9:05 AM - StreetInsider
Myriad Genetics launches Prolaris + AI prostate cancer test
May 26, 2026 4:06 PM - StreetInsider
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
May 26, 2026 4:05 PM - StreetInsider
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
May 15, 2026 11:00 AM - Globe NewsWire
Form 4 MYRIAD GENETICS INC For: May 14 Filed by: Bisaro Paul
May 14, 2026 5:17 PM - SEC Filing
Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: STATE STREET CORP
May 12, 2026 11:38 AM - SEC Filing
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
May 7, 2026 4:05 PM - StreetInsider
Myriad Genetics (MYGN) PT Lowered to $10 at Craig-Hallum
May 6, 2026 9:35 AM - StreetInsider
Myriad Genetics (MYGN) PT Lowered to $5.50 at Wells Fargo
May 6, 2026 8:49 AM - StreetInsider
Myriad Genetics (MYGN) PT Lowered to $6 at TD Cowen
May 6, 2026 8:20 AM - StreetInsider
Form 10-Q MYRIAD GENETICS INC For: Mar 31
May 6, 2026 6:08 AM - SEC Filing
Myriad Genetics (MYGN) Misses Q1 EPS by 2c ; Offers Guidance
May 6, 2026 2:50 AM - StreetInsider
Form 8-K MYRIAD GENETICS INC For: May 05
May 5, 2026 4:09 PM - SEC Filing
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
May 5, 2026 4:05 PM - StreetInsider
Form 4 MYRIAD GENETICS INC For: May 01 Filed by: Donnelly Brian J
May 4, 2026 4:36 PM - SEC Filing
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
April 30, 2026 9:05 AM - Globe NewsWire
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
April 28, 2026 4:05 PM - StreetInsider
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
April 16, 2026 11:45 AM - Globe NewsWire
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
April 16, 2026 9:15 AM - StreetInsider
Form 4 MYRIAD GENETICS INC For: Apr 14 Filed by: Verratti Mark
April 15, 2026 4:21 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Apr 14 Filed by: Muzzey Dale
April 15, 2026 4:20 PM - SEC Filing
Form ARS MYRIAD GENETICS INC For: Dec 31
April 14, 2026 5:06 PM - SEC Filing
Form DEFA14A MYRIAD GENETICS INC
April 14, 2026 5:03 PM - SEC Filing
Form DEF 14A MYRIAD GENETICS INC For: Dec 31
April 14, 2026 5:02 PM - SEC Filing
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
April 14, 2026 9:15 AM - StreetInsider
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
April 9, 2026 9:15 AM - StreetInsider
Form SCHEDULE 13G/A MYRIAD GENETICS INC Filed by: BlackRock, Inc.
April 7, 2026 1:30 PM - SEC Filing
Form SCHEDULE 13G/A MYRIAD GENETICS INC Filed by: VANGUARD GROUP INC
March 27, 2026 10:49 AM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Mar 22 Filed by: Muzzey Dale
March 23, 2026 4:23 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Mar 22 Filed by: Verratti Mark
March 23, 2026 4:23 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Mar 22 Filed by: Wheeler Benjamin Richard
March 23, 2026 4:23 PM - SEC Filing
Myriad Genetics receives FDA approval for MyChoice CDx as Zejula companion test
March 17, 2026 4:05 PM - StreetInsider
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
March 17, 2026 4:05 PM - StreetInsider
Form 4 MYRIAD GENETICS INC For: Mar 13 Filed by: Haas Kevin Richard
March 16, 2026 5:58 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Mar 12 Filed by: Muzzey Dale
March 16, 2026 5:06 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Mar 12 Filed by: Donnelly Brian J
March 16, 2026 5:06 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Mar 12 Filed by: Solaiman Shereen
March 16, 2026 5:06 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Mar 12 Filed by: Wheeler Benjamin Richard
March 16, 2026 5:06 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Mar 12 Filed by: Fox Jennifer Lynne
March 16, 2026 5:06 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Mar 12 Filed by: Verratti Mark
March 16, 2026 5:06 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Mar 12 Filed by: Raha Samraat S.
March 16, 2026 5:06 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Mar 09 Filed by: Raha Samraat S.
March 9, 2026 7:03 PM - SEC Filing
Full Article List